Congress Park Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$884K Buy
5,585
+160
+3% +$21.6K 0.24% 67
2026
Q1
$693K Buy
5,425
+535
+11% +$66.8K 0.21% 75
2025
Q4
$596K Buy
+4,890
New +$561K 0.18% 84

Other funds holding XBI

Congress Park Capital's XBI Position: Q2 2026 in Review

Congress Park Capital increased its State Street SPDR S&P Biotech ETF (XBI) stake by 2.9% in Q2 2026, buying an estimated $21.6K and bringing the position to 5,585 shares worth $884K. The position accounts for 0.24% of the portfolio, ranked #67.

Congress Park Capital first reported a position in XBI in Q4 2025 and has held it in 3 quarters since. 391 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Congress Park Capital held 5,585 shares of State Street SPDR S&P Biotech ETF worth $884K as of Q2 2026.
  • Congress Park Capital bought 160 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $21.6K.
  • State Street SPDR S&P Biotech ETF made up 0.24% of Congress Park Capital's portfolio in Q2 2026, its #67 holding.
  • Congress Park Capital first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and has held it in 3 quarters since.
  • 391 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Congress Park Capital's 13F filing for Q2 2026, filed 14 Jul 2026.